195 related articles for article (PubMed ID: 8546054)
21. Selective induction of apoptosis with proton pump inhibitor in gastric cancer cells.
Yeo M; Kim DK; Kim YB; Oh TY; Lee JE; Cho SW; Kim HC; Hahm KB
Clin Cancer Res; 2004 Dec; 10(24):8687-96. PubMed ID: 15623654
[TBL] [Abstract][Full Text] [Related]
22. [Recent topics on important drugs for H. pylori eradication: Pantoprazole sodium].
Okazaki K; Mori S; Tahashi K
Nihon Rinsho; 2005 Nov; 63 Suppl 11():354-60. PubMed ID: 16363559
[No Abstract] [Full Text] [Related]
23. The H+, K(+)-ATPase inhibitor pantoprazole (BY1023/SK&F96022) interacts less with cytochrome P450 than omeprazole and lansoprazole.
Simon WA; Büdingen C; Fahr S; Kinder B; Koske M
Biochem Pharmacol; 1991 Jul; 42(2):347-55. PubMed ID: 1650212
[TBL] [Abstract][Full Text] [Related]
24. [Are proton pump inhibitors safe?].
Creutzfeldt W
Internist (Berl); 1994 Dec; 35(12):1137-46. PubMed ID: 7883517
[No Abstract] [Full Text] [Related]
25. Influence of Helicobacter pylori eradication therapy on 13C aminopyrine breath test: comparison among omeprazole-, lansoprazole-, or pantoprazole-containing regimens.
Giannini E; Romagnoli P; Fasoli A; Chiarbonello B; Malfatti F; Botta F; Risso D; Lantieri PB; Savarino V; Testa R
Am J Gastroenterol; 2000 Oct; 95(10):2762-7. PubMed ID: 11051345
[TBL] [Abstract][Full Text] [Related]
26. Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats.
Katashima M; Yamamoto K; Sugiura M; Sawada Y; Iga T
Drug Metab Dispos; 1995 Jul; 23(7):718-23. PubMed ID: 7587960
[TBL] [Abstract][Full Text] [Related]
27. The gastric H,K-ATPase blocker lansoprazole is an inhibitor of chloride channels.
Schmarda A; Dinkhauser P; Gschwentner M; Ritter M; Fürst J; Scandella E; Wöll E; Laich A; Rossmann H; Seidler U; Lang F; Paulmichl M
Br J Pharmacol; 2000 Feb; 129(3):598-604. PubMed ID: 10711360
[TBL] [Abstract][Full Text] [Related]
28. Effects of IY-81149, a newly developed proton pump inhibitor, on gastric acid secretion in vitro and in vivo.
Kwon D; Chae JB; Park CW; Kim YS; Lee SM; Kim EJ; Huh IH; Kim DY; Cho KD
Arzneimittelforschung; 2001; 51(3):204-13. PubMed ID: 11304936
[TBL] [Abstract][Full Text] [Related]
29. Proton pump inhibitors: an update.
Vanderhoff BT; Tahboub RM
Am Fam Physician; 2002 Jul; 66(2):273-80. PubMed ID: 12152963
[TBL] [Abstract][Full Text] [Related]
30. Effect of four lansoprazole dose levels and one dosage regimen of omeprazole on 24-hour intragastric pH in healthy subjects.
Timmer W; Ripke H; Kleist P; Ehrlich A; Wieckhorst G; Lücker PW; Fuder H
Methods Find Exp Clin Pharmacol; 1995 Sep; 17(7):489-95. PubMed ID: 8577212
[TBL] [Abstract][Full Text] [Related]
31. Pantoprazole lacks interaction with antipyrine in man, either by inhibition or induction.
De Mey C; Meineke I; Steinijans VW; Huber R; Hartmann M; Bliesath H; Wurst W
Int J Clin Pharmacol Ther; 1996 May; 34(1 Suppl):S58-66. PubMed ID: 8793604
[TBL] [Abstract][Full Text] [Related]
32. Effects of proton pump inhibitors on thyroid hormone metabolism in rats: a comparison of UDP-glucuronyltransferase induction.
Masubuchi N; Hakusui H; Okazaki O
Biochem Pharmacol; 1997 Dec; 54(11):1225-31. PubMed ID: 9416973
[TBL] [Abstract][Full Text] [Related]
33. [Discovery and development of the proton pump inhibitor].
Igata H; Okabe S
Nihon Rinsho; 1992 Jan; 50(1):11-7. PubMed ID: 1311779
[TBL] [Abstract][Full Text] [Related]
34. Restoration of acid secretion following treatment with proton pump inhibitors.
Shin JM; Sachs G
Gastroenterology; 2002 Nov; 123(5):1588-97. PubMed ID: 12404233
[TBL] [Abstract][Full Text] [Related]
35. Pantoprazole therapy in the long-term management of severe acid peptic disease: clinical efficacy, safety, serum gastrin, gastric histology, and endocrine cell studies.
Bardhan KD; Cherian P; Bishop AE; Polak JM; Romanska H; Perry MJ; Rowland A; Thompson M; Morris P; Schneider A; Fischer R; Ng W; Lühmann R; McCaldin B
Am J Gastroenterol; 2001 Jun; 96(6):1767-76. PubMed ID: 11419827
[TBL] [Abstract][Full Text] [Related]
36. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents.
Besancon M; Simon A; Sachs G; Shin JM
J Biol Chem; 1997 Sep; 272(36):22438-46. PubMed ID: 9278394
[TBL] [Abstract][Full Text] [Related]
37. Progress with proton pump inhibition.
Bell NJ; Hunt RH
Yale J Biol Med; 1992; 65(6):649-57;discussion 689-92. PubMed ID: 1341069
[TBL] [Abstract][Full Text] [Related]
38. [Submicroscopic aspects of the mechanism of inhibitors of H+/K+-ATPase in gastric parietal cells].
Morozov IA
Eksp Klin Gastroenterol; 2002; (3):94-100, 122. PubMed ID: 12353402
[TBL] [Abstract][Full Text] [Related]
39. In vivo cytochrome P 450 interactions of the newly developed H+/K(+)-ATPase inhibitor pantoprazole (BY 1023/SK&F 96022) compared to other antiulcer drugs.
Hanauer G; Graf U; Meissner T
Methods Find Exp Clin Pharmacol; 1991; 13(1):63-7. PubMed ID: 1651432
[TBL] [Abstract][Full Text] [Related]
40. Reduction of pentagastrin stimulated acid output: a suitable method to predict efficacy of an irreversible proton pump inhibitor in peptic ulcer disease?
Bliesath H; Simon B; Hartmann M; Müller P; Schneider A; Lühmann R; Wurst W
Int J Clin Pharmacol Ther Toxicol; 1992 Nov; 30(11):439. PubMed ID: 1337063
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
